Janssen’s interlukin-23 (IL-23) inhibitor ‘Tremfya (guselkumab)’ will be reimbursed from May 1st for the treatment of palmoplantar pustulosis.

The reimbursement will apply to patients over the age of 18 years who were diagnosed with moderate to severe palmoplantar pustulosis that has lasted for more than 6 months that ▲ have a Palmoplantar Pustulosis Area and Severity Index (PPPASI) score of 12 or higher and have no response to Acitretin for at least 3 months or had to discontinue treatment due to side effects(medical report required); or ▲have a PPPASI score of 12 or higher and show no response to phototherapy for at least three months or had to discontinue treatment due to side effects;<